Journal
CANCERS
Volume 9, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/cancers9020018
Keywords
photodynamic therapy; doxorubicin; pheophorbide a; synergic treatment; HeLa cells
Categories
Funding
- Ministerio de Economia y Competitividad (Spain) [CTQ2013-48767-C3-1-R, CTQ2013-48767-C3-3-R]
- Obra Social la Caixa through Universitat Ramon Llull [2016-URL-Trac-013]
- European Social Funds
- Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya [2016 FI_B1 00021]
Ask authors/readers for more resources
A combination of therapies to treat cancer malignancies is at the forefront of research with the aim to reduce drug doses (ultimately side effects) and diminish the possibility of resistance emergence given the multitarget strategy. With this goal in mind, in the present study, we report the combination between the chemotherapeutic drug doxorubicin (DOXO) and the photosensitizing agent pheophorbide a (PhA) to inactivate HeLa cells. Photophysical studies revealed that DOXO can quench the excited states of PhA, detracting from its photosensitizing ability. DOXO can itself photosensitize the production of singlet oxygen; however, this is largely suppressed when bound to DNA. Photodynamic treatments of cells incubated with DOXO and PhA led to different outcomes depending on the concentrations and administration protocols, ranging from antagonistic to synergic for the same concentrations. Taken together, the results indicate that an appropriate combination of DOXO with PhA and red light may produce improved cytotoxicity with a smaller dose of the chemotherapeutic drug, as a result of the different subcellular localization, targets and mode of action of the two agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available